



November 16, 2005 10:01 AM US Eastern Timezone

Correlagen Diagnostics and Cerner Corporation Collaborate to Bring Genetic Testing to Clinical Practice

BIOWIRE2K

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 16, 2005--Correlagen Diagnostics, Inc. and Cerner Corporation announced today that they have signed an agreement that will enable Cerner's clients to order Correlagen's genetic tests and to receive results through Cerner Millennium(R) and other Cerner(R) solutions.

Correlagen Diagnostics, a clinical reference laboratory, develops and performs DNA sequence based testing for genes where variation is correlated with disease, and knowledge of patient genotype facilitates diagnosis and treatment. Correlagen uses a unique dynamic approach to genetic testing, which includes providing updated interpretations of patient results as the knowledge of genetic variation and its significance to diagnosis and treatment evolves.

"Correlagen is pleased to be able to provide its genetic testing services through the leading supplier of healthcare information technology," said David Margulies, chief executive officer of Correlagen Diagnostics, Inc. "By collaborating with Cerner, Correlagen will advance its goal of making the benefits of its unique testing readily accessible to physicians for use in clinical care," added Dr. Margulies.

"As genetic testing becomes an increasingly important part of clinical practice, information systems that can facilitate the accurate and rapid transmission of orders for the correct genetic test will become necessary," said J.P. Fingado, Cerner vice president and general manager. "This relationship with Correlagen provides an advanced electronic channel through Cerner Millennium solutions that allows a physician to select and accurately transmit a genetic test order to the reference lab."

Cerner believes this is the first of several opportunities to bring the latest in genomics to the practice of medicine. By leveraging its expertise in healthcare information technology and Correlagen's capabilities in gene sequencing and variant analysis, Cerner clients will be able to provide the benefits of new genetic insights to healthcare.

Cerner Corp. is taking the paper chart out of healthcare, eliminating error, variance and waste in the care process. With more than 1,500 clients worldwide, Cerner is the leading supplier of healthcare information technology. The following are trademarks of Cerner: Cerner, Cerner's logo and Cerner Millennium.
NASDAQ: CERN. www.cerner.com.

Correlagen Diagnostics, Inc., develops and commercializes genetic testing services, using a high throughput automated approach that incorporates sequencing, variant analysis and information technology. By focusing on Genes That Matter(TM) -- genes where variation is correlated with disease and where testing would impact diagnosis and treatment -- Correlagen is accelerating and increasing the use of genetic testing in clinical practice. Correlagen Diagnostics is based in Cambridge, Massachusetts. www.correlagen.com

Correlagen Diagnostics, Inc.
Joyce S. Samet
617-577-0152
jsamet@correlagen.com